170 related articles for article (PubMed ID: 29882724)
1. Celastrol as a pentacyclic triterpenoid with chemopreventive properties.
Yadav P; Jaswal V; Sharma A; Kashyap D; Tuli HS; Garg VK; Das SK; Srinivas R
Pharm Pat Anal; 2018 Jul; 7(4):155-167. PubMed ID: 29882724
[TBL] [Abstract][Full Text] [Related]
2. Ursolic acid in cancer prevention and treatment: molecular targets, pharmacokinetics and clinical studies.
Shanmugam MK; Dai X; Kumar AP; Tan BK; Sethi G; Bishayee A
Biochem Pharmacol; 2013 Jun; 85(11):1579-87. PubMed ID: 23499879
[TBL] [Abstract][Full Text] [Related]
3. Molecular targets of celastrol in cancer: Recent trends and advancements.
Kashyap D; Sharma A; Tuli HS; Sak K; Mukherjee T; Bishayee A
Crit Rev Oncol Hematol; 2018 Aug; 128():70-81. PubMed ID: 29958633
[TBL] [Abstract][Full Text] [Related]
4. Celastrol as an emerging anticancer agent: Current status, challenges and therapeutic strategies.
Wang C; Dai S; Zhao X; Zhang Y; Gong L; Fu K; Ma C; Peng C; Li Y
Biomed Pharmacother; 2023 Jul; 163():114882. PubMed ID: 37196541
[TBL] [Abstract][Full Text] [Related]
5. The effect of celastrol, a triterpene with antitumorigenic activity, on conformational and functional aspects of the human 90kDa heat shock protein Hsp90α, a chaperone implicated in the stabilization of the tumor phenotype.
Zanphorlin LM; Alves FR; Ramos CH
Biochim Biophys Acta; 2014 Oct; 1840(10):3145-52. PubMed ID: 24954307
[TBL] [Abstract][Full Text] [Related]
6. Oleanane-, ursane-, and quinone methide friedelane-type triterpenoid derivatives: Recent advances in cancer treatment.
Salvador JAR; Leal AS; Valdeira AS; Gonçalves BMF; Alho DPS; Figueiredo SAC; Silvestre SM; Mendes VIS
Eur J Med Chem; 2017 Dec; 142():95-130. PubMed ID: 28754470
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of NF-kappa B activation through targeting I kappa B kinase by celastrol, a quinone methide triterpenoid.
Lee JH; Koo TH; Yoon H; Jung HS; Jin HZ; Lee K; Hong YS; Lee JJ
Biochem Pharmacol; 2006 Nov; 72(10):1311-21. PubMed ID: 16984800
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of 3- and 29-substituted celastrol derivatives and structure-activity relationship studies of their cytotoxic activities.
Shan WG; Wang HG; Chen Y; Wu R; Wen YT; Zhang LW; Ying YM; Wang JW; Zhan ZJ
Bioorg Med Chem Lett; 2017 Aug; 27(15):3450-3453. PubMed ID: 28587825
[TBL] [Abstract][Full Text] [Related]
9. A Link Between Chemical Structure and Biological Activity in Triterpenoids.
Zang L; Xu H; Huang C; Wang C; Wang R; Chen Y; Wang L; Wang H
Recent Pat Anticancer Drug Discov; 2022; 17(2):145-161. PubMed ID: 33982656
[TBL] [Abstract][Full Text] [Related]
10. Molecular modulators of celastrol as the keystones for its diverse pharmacological activities.
Ng SW; Chan Y; Chellappan DK; Madheswaran T; Zeeshan F; Chan YL; Collet T; Gupta G; Oliver BG; Wark P; Hansbro N; Hsu A; Hansbro PM; Dua K; Panneerselvam J
Biomed Pharmacother; 2019 Jan; 109():1785-1792. PubMed ID: 30551432
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory action of Celastrol on hypoxia-mediated angiogenesis and metastasis via the HIF-1α pathway.
Huang L; Zhang Z; Zhang S; Ren J; Zhang R; Zeng H; Li Q; Wu G
Int J Mol Med; 2011 Mar; 27(3):407-15. PubMed ID: 21249310
[TBL] [Abstract][Full Text] [Related]
12. Role of Pentacyclic Triterpenoid Acids in the Treatment of Bladder Cancer.
Ghosh A; Panda CK
Mini Rev Med Chem; 2022; 22(9):1331-1340. PubMed ID: 34719363
[TBL] [Abstract][Full Text] [Related]
13. Folic acid-modified celastrol nanoparticles: synthesis, characterization, anticancer activity in 2D and 3D breast cancer models.
Law S; Leung AW; Xu C
Artif Cells Nanomed Biotechnol; 2020 Dec; 48(1):542-559. PubMed ID: 32054336
[TBL] [Abstract][Full Text] [Related]
14. Ursolic Acid in Cancer Treatment and Metastatic Chemoprevention: From Synthesized Derivatives to Nanoformulations in Preclinical Studies.
Zou J; Lin J; Li C; Zhao R; Fan L; Yu J; Shao J
Curr Cancer Drug Targets; 2019; 19(4):245-256. PubMed ID: 30332961
[TBL] [Abstract][Full Text] [Related]
15. Celastrol and attenuation of tumor growth in systemic malignancies: a clinical perspective.
Kapoor S
J Cell Physiol; 2014 Feb; 229(2):258. PubMed ID: 23765848
[No Abstract] [Full Text] [Related]
16. Control of autoimmune inflammation by celastrol, a natural triterpenoid.
Venkatesha SH; Dudics S; Astry B; Moudgil KD
Pathog Dis; 2016 Aug; 74(6):. PubMed ID: 27405485
[TBL] [Abstract][Full Text] [Related]
17. Bioactive Pentacyclic Triterpenes Trigger Multiple Signalling Pathways for Selective Apoptosis Leading to Anticancer Efficacy: Recent Updates and Future Perspectives.
Banerjee J; Samanta S; Ahmed R; Dash SK
Curr Protein Pept Sci; 2023; 24(10):820-842. PubMed ID: 37073661
[TBL] [Abstract][Full Text] [Related]
18. Synergistic anticancer effects of triptolide and celastrol, two main compounds from thunder god vine.
Jiang QW; Cheng KJ; Mei XL; Qiu JG; Zhang WJ; Xue YQ; Qin WM; Yang Y; Zheng DW; Chen Y; Wei MN; Zhang X; Lv M; Chen MW; Wei X; Shi Z
Oncotarget; 2015 Oct; 6(32):32790-804. PubMed ID: 26447544
[TBL] [Abstract][Full Text] [Related]
19. Molecular targets of celastrol derived from Thunder of God Vine: potential role in the treatment of inflammatory disorders and cancer.
Kannaiyan R; Shanmugam MK; Sethi G
Cancer Lett; 2011 Apr; 303(1):9-20. PubMed ID: 21168266
[TBL] [Abstract][Full Text] [Related]
20. Celastrol and Its Role in Controlling Chronic Diseases.
Venkatesha SH; Moudgil KD
Adv Exp Med Biol; 2016; 928():267-289. PubMed ID: 27671821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
